Companies offering sequencing-based trisomy 21 tests are Illumina's largest clinical customers, CEO Jay Flatley said this week during a conference call discussing Illumina's 2012 third-quarter earnings.

Additionally, customers purchasing the MiSeq for targeted sequencing assay development are another significant clinical driver.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.